As Merck & Co. rolls out a…
As Merck & Co. rolls out a widespread cost-cutting initiative, [...]
As Merck & Co. rolls out a widespread cost-cutting initiative, [...]
Quoin Pharmaceuticals has ended development of two programs, pulling back [...]
Bausch Health has struck a deal to buy Durect for [...]
After assuring investors last week that beleaguered Sarepta Therapeutics would [...]
After months of searching for strategic options, Adaptimmune is offloading [...]
MapLight Therapeutics has raised a $372.5 million series D round, [...]
Chinese biotech Leads Biolabs has hit the Hong Kong stock [...]
Bristol Myers Squibb has raided AstraZeneca to find its next [...]
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s [...]
A phase 2 trial of Memo Therapeutics’ kidney transplant drug [...]